Published in Mental Health Business Week, September 3rd, 2005
FluoroPharma is an emerging diagnostic discovery company with proprietary PET technology focused primarily on the diagnosis of cardiovascular disease. In 2004, FluoroPharma agreed to grant BLSI a right of participation in the event that FluoroPharma pursued a development and/or sublicensing agreement for its imaging agents with an established biotechnology or pharmaceutical company.
BLSI is primarily focused on developing products for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.